Medios Ag · XETR:ILM1
Medios — Q1 2026 Earnings Presentation
28 slides from Medios's earnings presentation, May 12, 2026
Slide 1: Q1 2026 Results
Q1 2026 Results Thomas Meier, CEO Stefan Bauerreis, CFO May 12, 2026
Slide 2: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2026, Strategy 4 Appendix 2
Slide 3: Executive Summary: Highlights Q1 2026
Executive Summary Highlights Q1 2026 Top line growth, albeit reduced margin. Margin impacted by price pressure and increased cost base. • Revenue up by 8.9% to €527.6m Financials • EBITDA pre decrease to €21.2m (-7.9%) resulting in an EBITDA pre margin of 4.0% • Significant improvement in operating
Slide 4: Revenue Grew, Albeit With Lower EBITDA pre Margin – Year 2026 Guidance Unchanged
Executive summary Revenue Grew, Albeit With Lower EBITDA pre Margin – Year 2026 Guidance Unchanged Revenue (€m) EBITDA pre¹ (€m) Comments YoY growth 8.9% YoY growth -7.9% • Revenue growth in all operational segments 549 • EBITDA pre reduction due to price pressure 538 24.0 and increased cost base 23
Slide 5: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2026, Strategy 4 Appendix 5
Slide 6: Q1 2026 – Strong Revenue Growth and Strong Cash Flow
Financial overview Q1 2026 – Strong Revenue Growth and Strong Cash Flow In € million Q1 2026 Q1 2025 ∆ in % / ppt Comments Revenue 527.6 484.7 8.9% • Significant growth in revenues supported by all operational Gross profit1 50.2 49.8 0.8% segments gross margin in % 9.5% 10.3% -0.8ppt • Slight decrea
Slide 7: Q1 2026 – Revenue Increase in All Operational Segments
Financial overview Q1 2026 – Revenue Increase in All Operational Segments Pharmaceutical Patient-specific International Services IFRS Group Supply ‘PS‘ Therapies ‘PST’ Business ‘IB' consolidation YoY in € million Q1 26 Q1 25 Q1 26 Q1 25 Q1 26 Q1 25 Q1 26 Q1 25 Q1 26 Q1 25 Q1 26 Q1 25 Segment revenue
Slide 8: PS: Revenue and EBITDA pre Increased
Executive Summary PS: Revenue and EBITDA pre Increased Comments Revenue (€m) EBITDA pre¹ (€m) • Price effects of various products led to YoY growth 9.0% YoY growth 2.8% slightly lower gross margin 14.6 • Medicinal cannabis business started later 449 13.8 than planned; market penetration on track 439
Slide 9: PST: Revenue Increase; EBITDA pre: Counter Measures to be Implemented
Financial overview PST: Revenue Increase; EBITDA pre: Counter Measures to be Implemented Revenue (€m) EBITDA pre¹ (€m) YoY growth 8.4% YoY growth -14.4% 60 60 56 56 6.3 54 54 6.0 55 5.7 5.4 50 45 4.0 40 35 30 11.3 10.5 10.9 7.5 8.9 25 20 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 2025 2026 2025 2026 1 EBITDA is
Slide 10: PST: YoY EBITDA pre Bridge
Financial overview PST: YoY EBITDA pre Bridge in €m 0,5 6,3 -0,5 -0,3 -0,2 5,4 -0,2 -0,2 1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization; EBITDA pre is adjusted for special charges for stock options, expenses for M&A activities, expenses for ERP-Sys
Slide 11: IB: Revenue up, EBITDA pre Margin on PY level
Financial overview IB: Revenue up, EBITDA pre Margin on PY level (after adjustment of sale of pharmacy in Q1 25) Revenue (€m) EBITDA pre¹ (€m) YoY growth 8.5% YoY growth -13.5% 8.2 45 7.3 7.1 6.5 6.3 43 43 42 40 18.4 19.0 15.7 15.8 14.7 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 2025 2026 2025 2026 1 EBITDA is d
Slide 12: IB: YoY EBITDA pre Bridge
Financial overview IB: YoY EBITDA pre Bridge in €m 2,7 -1,6 7,3 -0,8 -0,6 6,2 -0,3 -0,4 1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization; EBITDA pre is adjusted for special charges for stock options, expenses for M&A activities, expenses for ERP-Syst
Slide 13: Financing Structure Q1 2026
Financial overview Financing Structure Q1 2026 • Syndicate loan concluded in Nov 2024 : €225m, consisting of • term loan of €125m, term: 5 yrs, annual redemption €25m; value as of 31 March 26: c. €94m and • Revolving credit facility (RCF) €100m, term 5 (+1 +1) yrs; €65m drawn as of 31 March 26, pote
Slide 14: Guidance 2026, Strategy
1 Executive Summary 2 Financial Overview 3 Guidance 2026, Strategy 4 Appendix “I am passionate about working for Medios because the provision and compounding of medicine that patients need is at the center of what we do.” 14
Slide 15: Guidance Confirmed
Guidance 2026 Guidance Confirmed Revenue in €bn EBITDA pre1 in €m Comments and assumptions • Revenue expected: €2.0 - €2.12bn Up to +2.0% Up to +9.6% based on organic growth of all operational segments. No major shift between segments expected • Operational expenses: x • Personnel expenses: 9% incre
Slide 16: PST: Exclusive Oncology Software Partnership
Strategy PST: Exclusive Oncology Software Partnership Value creation + • Establish a digital workflow and –ordering system to increase quality and reduce cost • Software platform to enable digital therapy planning, dose calculation and ordering • Harmonize and facilitate structured communication bet
Slide 17: IB: New Product Launch – Medicine Shortage
Strategy IB: New Product Launch – Medicine Shortage Dipyridamol 100mg capsules: Antiplatelet medicine that prevents a type of blood cell (platelets) sticking together and forming a dangerous blood clot Shortage • Late 2025: risk of shortage Dipyridamol 200mg extended-release capsules • Market demand
Slide 18: Legislative Activities with a (Potential) Impact on Medios (1/2)
Strategy Legislative Activities with a (Potential) Impact on Medios (1/2) 1. Drug Price regulation („Hilfstaxe“) • German Association of Pharmacists (“Deutscher Apotheker Verband, DAV”) terminated the contractual agreement with the German Health Insurance Association (“Gesetzlicher Krankenkassenverb
Slide 19: Legislative Activities with a (Potential) Impact on Medios (2/2)
Strategy Legislative Activities with a (Potential) Impact on Medios (2/2) 4. Health Security Act (“Gesundheitssicherstellungsgesetz, GeSiG”) • Bundles and legislates activities to increase the resilience of the Health Care System during crises and in wartime by e.g. stipulating minimum stock quantit
Slide 20: Focus Activities 2026
Guidance 2026 Focus Activities 2026 One Team Medios • Harmonize business- & planning processes for compounding & pharmacy supply business • ERP/SAP(S4HANA) roll-out for Medios Pharma • Ensure better insights and teamwork resulting in faster decisions Operational excellence • Network optimization - b
Slide 21: Medios 2nd Capital Markets Day
Medios 2nd Capital Markets Day Date: 28-29 Sep 2026 Where: Breda, The Netherlands WELCOME AT Ceban in Breda 21
Slide 22: Appendix
1 Executive Summary 2 Financial Overview 3 Guidance 2026, Strategy 4 Appendix “I work for Medios because I can contribute to patient care that meets the highest quality standards.” 22
Slide 23: Key Figures (1/2)
Appendix Key Figures (1/2) in € thousand Q1 2026 Q1 2025 ∆ in % Revenue 527,621 484,657 8.9% Pharmaceutical Supply 424,251 389,236 9.0% Patient-Specific Therapies 60,445 55,762 8.4% International 42,988 39,543 8.7% Services 132 116 13.8% EBITDA 19,092 21,762 -12.3% Margin (in % of Revenue) 3.6% 4.5%
Slide 24: Key Figures (2/2)
Appendix Key Figures (2/2) in € thousand Q1 2026 Q1 2025 ∆ in % Earnings per share (in €) Undiluted 0.20 0.25 -20.0% Diluted 0.20 0.25 -20.0% Adjusted 2 0.44 0.46 -4.3% Investments (CAPEX) -2,594 -1,247 >100.0% Cash flow from operating activities 12,480 3,563 >100.0% Free cash flow3 (before M&A) 9,8
Slide 25: The Medios share Shareholder Structure
Appendix The Medios share Shareholder Structure 65.2% Free float1 Basic Information • 6.4% Janus Henderson • 6.1% Axxion • 2.99% SEB Investment Share Capital €25,505,723 • 3.9% Treasury shares2 • 2.4% Paladin Asset Management No. of shares 25,505,723 Free float 19.7% Martin Hesse3 Share class No-par
Slide 26: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations Phone +49 30 232 566 800 Claudia.Nickolaus@medios.group 26
Slide 27: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 28: Q1 2026 Results
Q1 2026 Results Thomas Meier, CEO Stefan Bauerreis, CFO May 12, 2026